Boundless Bio, Inc. (BOLD) stock intrinsic value fair value estimate & owner earnings analysis

Boundless Bio is a clinical-stage cancer drug developer built around extrachromosomal DNA (ecDNA), circular DNA outside the chromosomes that helps some tumors resist treatment. It has no approved products and has never had revenue. In response to clinical data, it cut back its portfolio, and as of January 2026 its research effort is concentrated on one drug candidate, BBI-940. Owner earnings have been consistently negative: about $(50) million in 2023, $(70) million in 2024 and $(56) million in 2025, or roughly $(2.51) per share in 2025. 2023 per-share figures are not comparable because the company only listed in March 2024. Stock-based pay of $6.1 million in 2025 is treated as a real cost. Because there is no revenue there is no growth spending to separate out, and all capital spending (small, $0.5 million in 2025) is treated as maintenance. The most recent full year was less negative than 2024, reflecting lower cash spending. Bear, base and bull cases are all valued at $0 per share. The reason is that nothing that produces cash can be named and evidenced today. The company says it has cash and short-term investments of over $100 million and expects that to fund operations into the second half of 2028. That cash is being consumed at roughly $47 million a year of operating cash outflow (2025), and a long-term facility lease adds fixed obligations. No product is approved, no revenue has ever been recorded, and BBI-940 has only reached the stage where initial proof-of-concept data are expected within the current cash runway. A positive trial readout would be a hoped-for event that has not happened, so it is left out of every case rather than credited at a discount. The bear case is that the trial does not support further development and the remaining cash is spent without producing a product that can be sold. The business as it exists today has no earnings to capitalise, so the bull case also carries no value. What would make this wrong: successful BBI-940 data followed by a funded partnership or approval path would create a business worth much more than zero. That is a possibility, not something the current record supports. The filings give two slightly different year-end cash totals ($117.6 million and $107.6 million); this does not change the conclusion. The estimate would change only if the business changed: for example clinical data supporting BBI-940 together with a signed agreement that pays the company. The margin-of-safety price is therefore $0 until then.